Thalassemia is a hereditary blood disorder in which a person’s body makes an abnormal form of hemoglobin, which is the protein molecule in red blood cells (RBCs), which carries oxygen. The disorder results in unwarranted damage of red blood cells, which leads to anemia. Anemia is a condition in which the body doesn’t have adequate amount of normal and healthy red blood cells. There are majorly two types of thalassemia based on these proteins known as the Alpha thalassemia and the Beta thalassemia. There is also a third type viz. Sickle beta thalassemia, which is like a combination of sickle cell disease and beta thalassemia.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/81283 .

Even though it is a rare genetic disorder, the number of people affected by it has been growing with time. While those with thalassemia minor have hardly any threat to their life and only require occasional blood transfusion to sustain, thalassemia major patients need to go for periodic transfusions for a sustained life. In case of infants, thalassemia major often leads to still birth or cause death shortly after the baby’s birth. Presently the only cure for thalassemia is a bone marrow transplantation therapy, which is done mostly for severe cases of thalassemia.

Purchase a copy of Global Thalassemia Market visit @ http://www.orbisresearch.com/contact/purchase/81283 For more information contact [email protected] .

The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific.

The report provides a comprehensive study of global thalassemia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global thalassemia industry is highly competitive consisting of several companies including the Lonza group, Acceleron Pharma, BlueBird Bio and Sangamo Biosciences etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Browse Complete Report @ http://www.orbisresearch.com/reports/index/global-thalassemia-market-report-2016-edition .

Some points from TOC:
1. Overview
1.1 Introduction
1.2 Types of Thalassemia
1.2.1 Alpha Thalassemia
1.2.2 Beta Thalassemia
1.2.3 Sickle Beta Thalassemia
1.3 Signs and Symptoms
1.4 Treatment Options
1.4.1 Blood Transfusion
1.4.2 Bone Marrow Transplant
2. Global Thalassemia Market
2.1 Global Thalassemia Incidence by Severity
2.2 Global Thalassemia Diagnosis by Category
2.3 Global Transfusion-Dependent β Thalassemia by Region
2.4 Global Thalassemia Market by Therapy
2.4.1 Global Bone Marrow Transplant Revenue
2.4.2 Global LentiGlobin BB305 Revenue
2.4.3 Global Luspatercept Revenue
3. Regional Analysis
3.1 The US Thalassemia Market
3.1.1 The US β Thalassemia Carrier Patient Population
3.1.2 The US β Thalassemia Major Patient Population
3.1.3 The US Transfusion-Dependent β Thalassemia Patients
3.1.4 The US β Thalassemia Sibling-Matched Stem Cell Transplant
3.2 Europe Thalassemia Market
3.2.1 Europe Transfusion-Dependent β Thalassemia Patients
3.2.2 Europe Transfusion-Dependent β-Thalassemia Major/Intermediate Patients

For any enquires before buying, connect with us @ [email protected]

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter: https://twitter.com/orbisresearch
Like us on Facebook: https://www.facebook.com/OrbisResearch